Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

Abstract

The staining of breast cancer with a new monoclonal antibody, NCRC 11, was studied in a series of 126 women with primary breast carcinoma. Tumour samples embedded in paraffin were tested, and the minimum duration of follow up was five years or to death. Altogether 119 tumours stained positively. There was a strong relation between the intensity of staining, divided on a four point scale, and patient survival. Patients whose tumours exhibited intense staining had an improved survival compared with those with less intensely staining tumours (p <0-0001). Staining related weakly to histological grade but not significantly to oestrogen receptor state or the pathological stage of lymph node disease. Mathematical analysis showed the relation to survival to be independent of the other known prognostic factors.Inclusion of intensity of staining with other factors in a prognostic index might permit a more accurate estimation of prognosis in patients with breast cancer.

Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein

“…Although, increased expression of MUC1 in conventional carcinoma correlated with low-grade cytology and good prognosis, [22][23][24][25][26] aberrant expression such as intracytoplasmic localization was shown by multiple studies to be associated with poor outcome, independent of tumor differentiation. [26][27][28][29][30] Intercellular/circumferential labeling was associated with a high incidence of lymph node metastases as well.…”

The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer

“…The synthesis of EMA by mammary acini and ducts is thought to be a specialised function and therefore tumours which contain EMA in abundance may be better differentiated and hence have a better prognosis than those in which it is less plentiful. In two studies using NCRC-1 and an immunoperoxidase method a relationship was demonstrated between well stained tumours and a favourable prognosis (Ellis et al, 1985. In a smaller study this relationship could not be confirmed (Angus et al, 1986) and no such study has been undertaken for 3E1.2.…”

“…Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody have been shown to relate to overall survival (Ellis et al, 1985) but the results have not been reproducible in other centres. In this study paraffin sections of 483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperoxidase system.…”

“…This paper describes the investigation of the prognostic value of monoclonal antibodies (MoAbs) NCRC-11 and 3E1.2 in 483 women with primary breast cancer. Both of these MoAbs are of the anti-Epithelial Membrane Antigen (EMA) type and their characterisations and clinical uses have been described elsewhere (Ellis et al, 1984(Ellis et al, , 1985Stacker et al, 1985Stacker et al, , 1988Stacker et al, , 1989. The synthesis of EMA by mammary acini and ducts is thought to be a specialised function and therefore tumours which contain EMA in abundance may be better differentiated and hence have a better prognosis than those in which it is less plentiful.…”

Polymorphic epithelial mucin from the sera of advanced breast cancer patients – isolation and partial characterisation

“…This antibody reacts with a variety of normal and malignant tissues of epithelial origin and immunocytochemical studies have shown that in malignant tissue there exists a direct relationship between the intensity of staining and patient survival (Ellis et al, 1985). The antigen defined by NCRC-l bears multiple epitopes for several anti-mucin MAbs and also displays the same molecular weight, tissue distribution and genetic polymorphism as PEM.…”